The National Pharmaceutical Pricing Authority (NPPA) is the Government of India's price regulator for medicines, tasked with keeping essential drugs affordable without driving manufacturers out of production.

Basic Details

  • Type: Attached office of the Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers.
  • Established: By a Government of India Resolution dated 29 August 1997.
  • Headquarters: New Delhi.
  • Governing Order: Drug (Prices Control) Order (DPCO), 2013, notified in May 2013.

Genesis

  • Why It Was Set Up: The NPPA was created to fix and revise prices of essential bulk drugs and formulations, and to enforce provisions of drug price control across India.
  • Successor Framework: It replaced earlier ad hoc price control mechanisms with a dedicated regulatory authority focused solely on pharmaceutical pricing.

Powers and Functions

  • Price Fixation: Sets ceiling prices for "scheduled formulations" — medicines listed in the DPCO's First Schedule, drawn from the National List of Essential Medicines (NLEM).
  • Price Monitoring: Tracks prices of "non-scheduled formulations" and restricts their annual price increase to a maximum of 10%, beyond which it can order a reduction.
  • Market Data: Maintains data on production, exports, and market share of drugs to identify emerging shortages.
  • Policy Advice: Advises the central government on changes needed to pharmaceutical pricing policy.

How Ceiling Prices Are Calculated

For scheduled formulations, the NPPA calculates the ceiling price using the Average Price to Retailer of all brands with at least a 1% market share, plus a 16% retailer margin. Manufacturers cannot raise non-scheduled drug prices by more than 10% a year without the NPPA's approval to exceed that cap.

Significance

  • Balancing Affordability and Availability: The NPPA's mandate to keep essential medicines affordable can clash with manufacturers' ability to absorb rising input costs, as seen in the 2026 cisplatin-carboplatin shortage, when a decade of roughly 22% price growth could not keep pace with a 225% rise in platinum costs.
  • Essential Medicine Access: By regulating prices of drugs on the NLEM, it directly shapes whether life-saving treatments like chemotherapy remain accessible to patients across income levels.